Pichia anomala fungaemia in immunocompromised children

Summary Pichia anomala is an emerging yeast causing serious nosocomial infections in newborn and immunocompromised children. We describe nosocomial port catheter infection due to P. anomala in three children who were receiving cancer chemotherapy, bloodstream infection in a preterm infant and in an...

Full description

Saved in:
Bibliographic Details
Published inMycoses Vol. 47; no. 5‐6; pp. 231 - 235
Main Authors Bakır, M., Çerikcioğlu, N., Tırtır, A., Berrak, S., Özek, E., Canpolat, C.
Format Journal Article
LanguageEnglish
Published Berling, Germany Blackwell Verlag, GmbH 01.06.2004
Subjects
Adolescent
amphotericin B
Antifungal Agents - therapeutic use
Child
children
Female
Fluconazole - therapeutic use
fungaemia
Fungemia - drug therapy
Fungemia - microbiology
Fungämie
Humans
Immunocompromised Host
immunosuppression
Immunsuppression
Infant
Infant, Newborn
Kindern
Male
nosocomial
Pichia - drug effects
Pichia - isolation & purification
Pichia anomala
Online AccessGet full text

Cover

More Information
Summary:Summary Pichia anomala is an emerging yeast causing serious nosocomial infections in newborn and immunocompromised children. We describe nosocomial port catheter infection due to P. anomala in three children who were receiving cancer chemotherapy, bloodstream infection in a preterm infant and in an infant with severe combined immunodeficiency. All patients were treated with amphotericin B. All isolates were susceptible to amphotericin B and fluconazole. No recurrence was observed during follow‐up in four of five patients. The common clinical feature in all of our patients was the presence of prior antimicrobial therapy. Zusammenfassung Pichia anomala gilt als opportunistischer Erreger nosokomialer Infektionen bei Neugeborenen und immunsupprimierten Kindern. Wir beschreiben nosokomiale Katheterinfektionen durch P. anomala bei drei Kindern mit Krebs, bei einer Frühgeburt und bei einem immunsupprimierten Säugling. Alle fünf Patienten hatten vorab antibakterielle Therapie erhalten und wurden durch Amphotericin B erfolgreich behandelt. Alle Isolate waren empfindlich für Amphotericin B und Fluconazol. In der Nachbeobachtungszeit wurde an vier fünf Patienten kein Rezidiv beobachtet.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:0933-7407
1439-0507
DOI:10.1111/j.1439-0507.2004.00962.x